Clinical implications of the expression of survivin and p53 in superficial transitional cell carcinoma of the bladder

Korean Journal of Urology

Volumn 50, Issue 1, 2009, Pages 12-17

  Kwak, Dong Yun ^a   Ha, Ji Yong ^a   Chang, Hyuk Soo ^a   Choi, Mi Sun ^a   Park, Choal Hee ^a   Kim, Chun Il ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Human BIRC5 protein; p53 genes; Urinary bladder neoplasms

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P53; SURVIVIN; TUMOR MARKER;

ADULT; AGE; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CHI SQUARE TEST; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; PROGNOSIS; PROTEIN EXPRESSION; STUDENT T TEST; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

EID: 59349096688     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2009.50.1.12     Document Type: Article

References (25)

1. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003;30:765-76
2. Lee ES, Lee CK, Lee C. Prognostic factors in superficial bladder tumor. Korean J Urol 1990;31:795-801
3. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083.6
4. Fradet Y, Lacombe L. Can biological markers predict recurrence and progression of superficial bladder cancer? Curr Opin Urol 2000;10:441-5
5. Peyromaure M, Weibing S, Sebe P, Verpillat P, Toubianc M, Dauge MC, et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 2002;59:409-13
6. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281-5
7. Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006; 13:122-6
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62
9. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-20
10. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631-5
11. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bc1-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6
12. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curt Opin Genet Dev 1996;6:12-8
13. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67: 2168-74
14. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27
15. Lowe SW, Ruley HE, Jacks T, Honsman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer angents. Cell 1993;74:957-67
16. Horowitz JM. Regulation of transcription by the retinoblastoma protein. Genes Chromosomes Cancer 1993;6:124-31
17. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-92
18. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calrnette-Guerin therapy: corrrelation to clinical outcomes. J Clin Oncol 1996;14:2646-52
19. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994;73:526-32
20. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78:1762-74
21. Pages F, Flam TA, Vieillefond A, Molinie V, Abeille X, Lazar V, et al. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol 1998;159:1079-84
22. Pfister C, Moore L, Allard P, Lame H, Lacombe L, Tetu B, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-84
23. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3
24. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-rnuscle-invasive urothelial cell carcinoma of the bladder. Urology 2007;70:482-6
25. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002;441:559-63